<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03886688</url>
  </required_header>
  <id_info>
    <org_study_id>HEC53856-P-01</org_study_id>
    <nct_id>NCT03886688</nct_id>
  </id_info>
  <brief_title>HEC53856 Phase 1 Study - Single and Multiple Oral Dosing in Healthy Volunteers</brief_title>
  <official_title>A Phase 1, Double-blind, Randomized, Placebo-controlled, Dose-escalation, Pharmacokinetic Study of Single and Multiple Oral Dosing of HEC53856, A Novel HIF-PHD Inhibitor, in Healthy Non-elderly Volunteers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunshine Lake Pharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunshine Lake Pharma Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety, tolerability and pharmacokinetics of HEC53856 after single or
      multiple oral administration, as well as the food effect on the pharmacokinetics, in healthy
      non-elderly subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase I, Single Center, Randomized, Double-blind, Placebo-controlled Study to
      Evaluate the Tolerability and Pharmacokinetics of HEC53856 capsule in Healthy Adult Subjects.
      The study consists of three parts, single dose ascending, multiple dose ascending and food
      effect testing. Within each part participants will be randomized to either drug or placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 14, 2019</start_date>
  <completion_date type="Actual">January 1, 2020</completion_date>
  <primary_completion_date type="Actual">January 1, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events [Safety and Tolerability]</measure>
    <time_frame>Up to Day 10 after last dose</time_frame>
    <description>To assess the safety and tolerability by incidence of treatment-emergent adverse events after a single dose or multiple doses of HEC53856 capsule</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC0-t</measure>
    <time_frame>Up to 96 hours after dosing</time_frame>
    <description>Area under the concentration versus time curve (AUC) from time zero to the time of the last quantifiable concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>Up to 96 hours after dosing</time_frame>
    <description>Maximum observed plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>Up to 96 hours after dosing</time_frame>
    <description>Time of the maximum observed plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T T½</measure>
    <time_frame>Up to 96 hours after dosing</time_frame>
    <description>Apparent terminal elimination half-life</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Vz/F</measure>
    <time_frame>Up to 96 hours after dosing</time_frame>
    <description>Apparent volume of distribution</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">116</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>single ascending</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug or placebo, oral, fast, single dose ascending</description>
  </arm_group>
  <arm_group>
    <arm_group_label>multiple ascending</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug or placebo, oral, fast, multiple dose ascending</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Food Effect</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug or placebo, oral, fed or fast, single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HEC53856</intervention_name>
    <description>oral administration</description>
    <arm_group_label>Food Effect</arm_group_label>
    <arm_group_label>multiple ascending</arm_group_label>
    <arm_group_label>single ascending</arm_group_label>
    <other_name>HEC53856 capsule</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>oral administration</description>
    <arm_group_label>Food Effect</arm_group_label>
    <arm_group_label>multiple ascending</arm_group_label>
    <arm_group_label>single ascending</arm_group_label>
    <other_name>HEC53856 matching placebo capsule</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy volunteers

          -  age: 18-45 years old(18 and 45 included).

          -  B.W. male&gt; 50kg, female&gt; 45kg, BMI - 18-28 kg/m^2

          -  females must not be pregnant and males and females must agree to use contraception
             during the study.

          -  able to give informed consent and comply with protocol.

          -  physical examination and vital signs without clinically significant abnormalities.

          -  agree to use contraceptive methods after informed consent acquisition through 6 months
             after the last administration of the study drug.

        Exclusion Criteria:

          -  history or presence of severe gastrointestinal or systemic disorders (e.g.
             respiratory, endocrine, immunological, dermatological, neurological, psychiatric,
             renal, hepatic disease etc.)

          -  history or presence of significant alcoholism or drug abuse within past 5 years

          -  smokers, who smoke more than 5 cigarettes per day within past 3 months

          -  heavy drinker, namely alcohol consumption are 14 units per week (1 unit = 285 mL of
             beer, or 25 mL of strong wine, or 100 mL of grape wine);

          -  donated blood or massive blood loss within 3 months before screening (＞450 mL）

          -  have any disease that increases the risk of bleeding or thrombus, such as acute
             gastritis or stomach and duodenal ulcers;

          -  clinically significant laboratory findings during screening

          -  history or presence of clinically significant ECG abnormalities

          -  participated in drug research study within past 3 months

          -  used over-the-counter/ prescription/ herbal medications/ supplements within past 14
             days.

          -  Strenuous activity (as assessed by the investigator) is prohibited from 2 weeks prior
             to admission until discharge from the unit.

          -  female in pregnancy or lactation.

          -  viral hepatitis（including CHB and CHC）and positive test result of anti-HIV Ab or
             syphilis.

          -  the investigator believes that the one should not be included
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ding Yanhua, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Hospital of Jilin University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>March 19, 2019</study_first_submitted>
  <study_first_submitted_qc>March 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2019</study_first_posted>
  <last_update_submitted>March 16, 2020</last_update_submitted>
  <last_update_submitted_qc>March 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

